Palbociclib–letrozole or palbociclib–fulvestrant as a therapy for patients over 70 years of age with metastatic HR+/HER2− breast cancer was evaluated in a clinical trial (NCT03633331, Table 1) evaluating the tolerability of these combinations. This evidence concerns the gene ERBB2 and breast carcinoma.